| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
The primary targets of Ethoxyacetic acid include testicular germ cells, where it induces apoptosis and disrupts spermatogenesis, similar to other alkoxyacetic acids. As a metabolite of 2-ethoxyethanol, it is responsible for the reproductive and developmental toxicity associated with exposure to the parent solvent. The compound may also interact with various enzymes involved in carboxylic acid metabolism. These targets make it relevant for toxicology and reproductive health research.
|
|---|---|
| ln Vitro |
In vitro, Ethoxyacetic acid induces apoptosis in testicular germ cells and other cell types. It is used in cell culture studies to investigate mechanisms of reproductive toxicity and to evaluate potential protective strategies against solvent-induced damage. The compound's effects on cell cycle regulation and apoptosis are studied. These in vitro activities support its use in toxicology and reproductive biology research.
|
| ln Vivo |
In vivo, Ethoxyacetic acid is the primary toxic metabolite responsible for the reproductive and developmental toxicity of 2-ethoxyethanol. Exposure to the compound in animal models results in testicular atrophy, decreased sperm count, and impaired fertility. The compound also causes developmental abnormalities following maternal exposure during pregnancy. Its toxicological effects are similar to those of methoxyacetic acid.
|
| Enzyme Assay |
In vitro enzyme assays for Ethoxyacetic acid are limited, as it is not a conventional enzyme inhibitor. Its formation from 2-ethoxyethanol can be studied using alcohol dehydrogenase and aldehyde dehydrogenase. Enzyme activity is measured spectrophotometrically. All assays include appropriate controls and reference compounds.
|
| Cell Assay |
In vitro cell-based assays for Ethoxyacetic acid are conducted using testicular germ cell lines or other relevant cell types. Cells are treated with compound concentrations ranging from 0.1-100 mM for 24-72 hours. Apoptosis is assessed by annexin V/PI staining and caspase activity assays. Cell viability is assessed using MTT assays. Experiments include vehicle controls and positive controls.
|
| Animal Protocol |
In vivo animal studies with Ethoxyacetic acid are conducted in rodent models to assess reproductive and developmental toxicity. The compound is administered via oral gavage or intraperitoneal injection at doses ranging from 50-500 mg/kg. Testicular weight, sperm count, and histopathology are assessed. Fetal abnormalities are evaluated in developmental toxicity studies. Each group consists of 6-10 animals with appropriate controls.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Ethoxyacetic acid include its formation as a metabolite of 2-ethoxyethanol through oxidation. Following absorption, it distributes widely to tissues, with the highest concentrations found in the testes. Elimination occurs primarily via renal excretion. Its pharmacokinetics are dose-dependent.
|
| Toxicity/Toxicokinetics |
Toxicological data for Ethoxyacetic acid indicate that it is a reproductive and developmental toxicant, causing testicular atrophy, decreased sperm production, and fetal abnormalities. It is similar in toxicity to methoxyacetic acid. Appropriate safety precautions should be taken during handling.
|
| Additional Infomation |
Ethoxyacetic acid is a liquid. (NTP, 1992)
Ethoxyacetic acid is a carboxylic acid. Ethoxyacetic acid has been reported to exist in the Montipora region, and relevant data are available. Ethoxyacetic acid is an alkoxyacetic acid and a metabolite of the industrial solvent 2-ethoxyethanol. It is used as a chemical intermediate and has been studied for its reproductive and developmental toxicity. Used in toxicology and reproductive health research. Not approved for therapeutic use; intended for research purposes only. |
| Molecular Formula |
C₄H₈O₃
|
|---|---|
| Molecular Weight |
104.10
|
| Exact Mass |
104.047
|
| CAS # |
627-03-2
|
| PubChem CID |
12301
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.102 g/mL at 25 °C(lit.)
|
| Boiling Point |
97-100 °C11 mm Hg(lit.)
|
| Flash Point |
208 °F
|
| Index of Refraction |
n20/D 1.419(lit.)
|
| LogP |
0.107
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
7
|
| Complexity |
60
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])C(=O)O[H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
YZGQDNOIGFBYKF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H8O3/c1-2-7-3-4(5)6/h2-3H2,1H3,(H,5,6)
|
| Chemical Name |
2-ethoxyacetic acid
|
| Synonyms |
Ethoxyacetic acid; Ethoxyacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~75 mg/mL (~720.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.75 mg/mL (36.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.75 mg/mL (36.02 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.75 mg/mL (36.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.6061 mL | 48.0307 mL | 96.0615 mL | |
| 5 mM | 1.9212 mL | 9.6061 mL | 19.2123 mL | |
| 10 mM | 0.9606 mL | 4.8031 mL | 9.6061 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
